Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal TP, Hemmingsen C, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews. 11 nov 2013, 11, s. CD008143.

Figure web 7: Trial sequential analysis for the trials exclusively dealing with glycaemic control on all-cause mortality.
Figure web 8: Trial sequential analysis for the trials exclusively dealing with glycaemic control on all-cause mortality including zero events.
Figure web 9: Trial sequential analysis for the trials exclusively dealing with glycaemic control on cardiovascular mortality.
Figure web 10: Funnel plot for cardiovascular mortality.
Figure web 11: Trial sequential analysis for all trials on non-fatal myocardial infarction.
Figure web 12: Trial sequential analysis for the trials exclusively dealing with glycaemic control on non-fatal myocardial infarction.
Figure web 13: Trial sequential analysis for all trials on amputation of lower extremity.
Figure web 14: Trial sequential analysis for the trials exclusively dealing with glycaemic control on amputation of lower extremity.
Figure web 15: Trial sequential analysis for all trials on microvascular complications as a composite outcome.
Figure web 16: Trial sequential analysis for the trials exclusively dealing with glycaemic control on microvascular complications as a composite outcome.
Figure web 17: Trial sequential analysis for all trials on nephropathy.
Figure web 18: Trial sequential analysis for the trials exclusively dealing with glycaemic control on nephropathy.
Figure web 19: Trial sequential analysis for all trials on retinopathy.
Figure web 20: Trial sequential analysis for the trials exclusively dealing with glycaemic control on retinopathy.
Figure web 21: Trial sequential analysis for all trials on retinal photocoagulation.
Figure web 22: Trial sequential analysis for all trials on serious adverse events.
Figure web 23: Trial sequential analysis for the trials exclusively dealing with glycaemic control on serious adverse events.
Figure web 24: Trial sequential analysis for all trials on mild hypoglycaemia.
Figure web 25: Trial sequential analysis for the trials exclusively dealing with glycaemic control on mild hypoglycaemia.
Figure web 26: Trial sequential analysis for all trials on severe hypoglycaemia.
Figure web 27: Trial sequential analysis for the trials exclusively dealing with glycaemic control on severe hypoglycaemia.